Albumin News and Research

RSS

Yttrium-90 to control hepatocarcinoma

The University Hospital at the University of Navarra is the only centre throughout the entire Spanish state for the treatment of liver tumours by means of radioembolisation and the one with the greatest accumulated experiences in the treatment throughout Europe.

10 Jul 2006

Advancing nanoparticle-based imaging and therapy of brain cancer

Brain cancer is one of the most difficult malignancies to detect and treat, in large part because of the difficulty in getting imaging and therapeutic agents past the so-called blood-brain barrier and into the brain.

9 May 2006

Plain language labels now required for eight top allergens

If you or someone in your family suffers from a food allergy, you know how difficult it can be to decipher the food label if the product contains an offending substance.

20 Apr 2006

Study shows mercury amalgam fillings pose no health concerns for children

There were no statistically significant differences in neuropsychological and neurobehavioral effects among children whose dental caries were treated with mercury amalgam fillings and those treated with a composite dental restorative material

18 Apr 2006

Minimal nutritional requirements for growing and maintaining human embryonic stem cells

Researchers at Yale have established the minimal nutritional requirements for growing and maintaining human embryonic stem cells, a recipe that is critical for clinical application and for developmental studies, according to a report in the Proceedings of the National Academy of Sciences.

11 Apr 2006

Newly discovered testosterone effect may act on prostate cancer

A newly-discovered mode of action of testosterone is showing great promise in the fight against prostate cancer, with tests showing a 60% reduction in tumor size in mice.

6 Apr 2006

Tobacco plants being used to produce human albumin

Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence.

27 Mar 2006

Simple method to diagnose preeclampsia

Researchers at Yale School of Medicine have found that analyzing proteins in urine is a simple and objective method to diagnose and classify preeclampsia (PE), a complication of pregnancy causing high blood pressure after 20 weeks of gestation.

5 Feb 2006

Kidney disease may be a more important risk factor for heart disease than is cholesterol

Jefferson researchers have found that mice with low levels of the protein hormone adiponectin may also have high levels of a protein called albumin which, in humans, may be a sign of kidney disease.

28 Nov 2005

Research points way to more effective delivery of medicine around the body

New research showing how drugs stick to a key protein in the bloodstream could help to create drugs that are delivered more effectively to organs in the body.

13 Oct 2005

New role for the blood protein serum amyloid P in the body's response to medical materials

Using a technique called proteomics, the researchers identified many of the blood proteins that stick (adsorb) to the surfaces of medical devices. Blood proteins that adsorb to the surfaces of materials unfold and can be recognized by the body, which then mounts a response against the device.

5 Oct 2005

Call for closer examination of a metabolic syndrome

Two major health organizations in Europe and the United States are calling for closer examination of a syndrome that has been widely believed to predict the risk of developing heart disease, questioning whether it has been appropriately defined and whether it is in fact a syndrome at all.

25 Aug 2005

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005

Link between PKC enzyme and kidney disease in diabetes confirmed

Researchers at Joslin Diabetes Center have investigated PKC-beta - a critical enzyme implicated in the devastating complications of type 1 and type 2 diabetes - for more than two decades.

12 Jun 2005

Link between hyperglycemia (high blood glucose), overexpression of PKC-beta 2 and kidney disease

Scientists at Joslin Diabetes Center have investigated PKC-beta -- a critical enzyme implicated in the devastating complications of type 1 and type 2 diabetes -- for more than two decades.

10 Jun 2005

Why different tissues in the human body vary in their susceptibility to "amyloid" diseases

Researchers at The Scripps Research Institute are reporting the results of a recent study that addresses why different tissues in the human body vary in their susceptibility to "amyloid" diseases, which include Alzheimer's disease and a cluster of ailments called the familial amyloidoses.

7 Apr 2005

New color-coded test for protein folding

Every protein--from albumin to testosterone--is folded into a unique, three-dimensional shape that allows it to function properly. Now Stanford University scientists have developed a simple test that instantly changes color when a protein molecule attached to a gold nanoparticle folds or unfolds.

28 Mar 2005

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005